Avon Foundation for Women launches competition to bring emerging breast cancer technologies to market

NewsGuard 100/100 Score

A world-wide competition to bring emerging breast cancer technologies to market is being launched by the Avon Foundation for Women, in partnership with the National Cancer Institute (NCI), part of the NIH, and the Center for Advancing Innovation. The Avon Foundation will fund $250,000 in grants to launch the Breast Cancer Start-up Challenge aimed at teams of business, legal, medical/scientific, engineering, and computer science students, as well as seasoned entrepreneurs.

The challenge will offer teams the opportunity to create strategic business plans and the potential to start new companies based on the development of 10 unlicensed breast cancer inventions by turning them into commercially marketed products. Breast cancer inventions include therapeutics, diagnostics, prognostics, one device, one vaccine, and a health IT invention, all from the NCI intramural program and Avon Foundation-funded university labs. The challenge will include up to 100 teams—10 teams for each of the 10 inventions— to compete. Each student team will be paired with entrepreneur-mentors to assist in the development of the business plans.

"The Breast Cancer Start-up Challenge is designed to accelerate and increase the volume of breast cancer inventions in development," said Marc Hurlbert, executive director of the Avon Foundation Breast Cancer Crusade. "In addition to improving public health, we hope to spur economic growth and provide universities a platform to develop their entrepreneurship-learning portfolios."

The challenge will begin on Oct. 1, 2013, in honor of Breast Cancer Awareness Month, with a call to universities to establish challenge teams. Teams accepted into the competition will have until January 2014 to submit a business plan for judging. Selected finalists will receive an award of $5,000 and will present a comprehensive business plan. Winning start-ups will be recognized in June 2014. It is anticipated that up to 30 successful start-ups will apply and be awarded funding from venture and other sources, which could range from $100,000 to over 1 million dollars.

Judges for this contest include:

Robert Berg, Senior Vice President, IRI
Katherine Bowdish, Ph.D., Vice President R&D and Head of Sunrise, Sanofi
Kapil Dhingra, MBBS, Managing Member, KAPital Consulting
Nick Donofrio, IBM Executive Vice President Innovation and Technology (Retired)
Terry J. Fetterhoff, Sr. Director, Head, US Chief Technology Office Diagnostics Division, Hoffmann-La Roche, Inc.
Mary Haak-Frendscho, Ph.D. Chief Executive Officer, Ingenica, Inc.
Eric Hale, J.D. M.S., MBA, Associate Director, Office of Clinical and Preclinical Development Partnerships, Center for Cancer Research, NCI
John D. Hewes, Ph. D. Technology Transfer Specialist, Technology Transfer Center, NCI
Marc Hurlbert, Ph.D. Executive Director, Avon Foundation Breast Cancer Crusade
Michael King Jolly, Pharm.D. Senior Vice President, Quintiles Innovation
Richard Lipkin, Venture Partner at Easton Capital Investment Group
James R. McCullough, Chief Executive Officer, Exosome Diagnostics
Carol Nacy, Founder and Chief Executive Officer, Sequella, Inc.
Christine K. Norton, Co-Founder, Minnesota Breast Cancer Coalition
Gil Price, M.D., Chief Executive Officer, Drug Safety Solutions
Thomas M. Stackhouse, Ph.D. Associate Director, Technology Transfer Center, NCI
George F. Tidmarsh, M.D., Ph.D. President, Chief Executive Officer, La Jolla Pharmaceutical Co.
Rosemarie Truman Founder and Chief Executive Officer, The Center for Advancing Innovation, INC.
"In addition to making an impact on breast cancer health, I believe this Challenge will fundamentally change the commercialization of NIH innovation and the business model of healthcare philanthropic funding," said George Tidmarsh, M.D., Ph.D. President, Chief Executive Officer and Secretary, La Jolla Pharmaceutical Co.

"Having worked with several organizations that launched monumental efforts, it's been exciting to see this Herculean startup challenge successfully catalyzed! I look forward to the outcomes that this Challenge will create," said Nick Donofrio, a retired IBM Executive Vice President of Innovation and Technology.

"The Business Plan and Start-up Challenge will create a new paradigm to link venture philanthropy and translational research to ignite economic growth and advance public health," said Rosemarie Truman, founder and CEO of The Center for Advancing Innovation. "The Avon Foundation for Women, the Technology Transfer Center of the NCI and The Center for Advancing Innovation are pioneering novel innovative models to create start-ups for promising inventions arising out of breast cancer research."

Source: The Center for Advancing Innovation (CAI) 

Comments

  1. Bernie Campbell Bernie Campbell United States says:

    To my knowledge, Avon Foundation does not test on animals. I hope this is part of the criteria for this Challenge.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases